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Treatment with intermittent calcitriol and calcium reduces bone
loss after renal transplantation.
Background. Bone loss occurs during the first 6 months after
renal transplantation (RT), and corticosteroid therapy plays an
important role. Although calcium plus vitamin D administra-
tion prevents corticosteroid-induced osteoporosis, its use in RT
recipients is limited by the risk of hypercalcemia.
Methods. This double-blind, randomized, and controlled
prospective intervention trial examined the effect of intermit-
tent calcitriol (0.5 lg/48 h) during the first 3 months after RT,
plus oral calcium supplementation (0.5 g/day) during 1 year with
calcium supplementation alone. The primary outcome mea-
sure was the change in bone mineral density (BMD) at 3 and
12 months after RT; we also explored whether the effect of cal-
citriol on BMD was different among vitamin D receptor (VDR)
genotypes (BsmI). Forty-five recipients were randomized to cal-
citriol therapy (CT) and 41 were randomized to placebo (PL).
Results. Both groups had a similar degree of pre-existing hy-
perparathyroidism (197 ± 229 vs. 191 ± 183 pg/mL), but a more
pronounced decrease of parathyroid hormone (PTH) levels af-
ter RT was observed in CT patients (at 3 months: 61.4 ± 42.2
vs. 85.7 ± 53.1 pg/mL, P = 0.02; at 12 months: 67.3 ± 33.7 vs.
82.6 ± 37 pg/mL; P = 0.08). CT patients preserved their BMD
at the total hip significantly better than those on PL (3 months:
0.04 ± 3.3 vs. −1.93 ± 3.2%, P = 0.01; 12 months: 0.32 ± 4.8
vs. −2.17 ± 4.4%, P = 0.03); significant differences were noted
at the intertrochanter, trochanter, and Ward’s triangle. Differ-
ences did not reach significance at the femoral neck. Two CT
patients (4.4%) and 4 PL patients (9.8%) developed a hyper-
calcemic episode during the first 3 months after RT. The effect
of CT on BMD at 3 months was more prominent in recipients
with the at-risk allele of the VDR gene (P = 0.03).
Conclusion. Therapy with low-dose calcium supplements
during 1 year, plus intermittent calcitriol for 3 months after RT,
is safe, decreases PTH levels more rapidly, and prevents bone
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loss at the proximal femur; a more pronounced effect is seen in
recipients with at least one at-risk allele of the VDR genotype.
Prospective studies have shown a rapid rate of bone
loss during the first 6 months after renal transplanta-
tion (RT) [1, 2]. Although mainly affecting the cancellous
bone compartment, consistent bone loss is also observed
at the femoral neck and cortical bone [3, 4]. The increased
rate of bone loss places the renal transplant recipient at
increased risk of fractures, underscoring the importance
of starting prophylaxis immediately after RT. Corticos-
teroid therapy plays an important role in the early bone
loss after RT [1], and persistent hyperparathyroidism, low
serum phosphorus levels, and alterations in vitamin D
metabolism are additional factors [5, 6].
A paucity of information exists regarding the effect of
different therapies in the prevention of early bone loss
after RT. Bisphosphonates are promising agents because
they improve bone mineral density (BMD) and reduce
the risk of vertebral fractures in costicosteroid-treated
patients [7]. Two studies have demonstrated that the bis-
phosphonates pamidronate [8] and ibandronate [4] can
prevent bone loss during the first post-transplantation
year. However, a significant number of dialysis patients
have low-turnover bone disease at the time of RT [9], and
the impact that further suppression of bone turnover has
on the mechanical integrity of bone is unknown.
Several studies have shown that vitamin D ther-
apy prevents bone loss in non-transplant patients with
corticosteroid-induced osteoporosis [10, 11]. However,
because of the concern about the risk of hypercalcemia,
the use of vitamin D in this setting has been limited. A
recent report has shown that treatment with low doses
of active vitamin D and calcium reduced bone loss at
the lumbar spine and proximal femur during the first
6 months after RT [12]. Although safe, severe
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hypercalcemia (>2.8 mmol/L) was slightly more frequent
in the treatment group [12].
Even among recipients with identical immunosuppres-
sive treatments, a wide variation in the rate of bone loss
is observed. Thus, post-transplantation bone loss reflects
variable individual susceptibility, resembling the poly-
genic determination of BMD in general. In fact, vitamin
D receptor (VDR) polymorphism has been shown to in-
fluence the rate of bone loss after transplantation both in
renal [13] and liver [14] recipients. Moreover, the BMD
response to calcium [15] or vitamin D supplementation
[16] has been shown to be influenced by VDR genotype
in non-renal patients.
In this double-blind, randomized, and controlled
prospective intervention trial, we compared the effect
of calcium alone versus calcium plus intermittent cal-
citriol therapy on the bone loss after RT. We reasoned
that intermittent calcitriol might minimize the risk of hy-
percalcemia. Finally, we explored whether the effect of
intermittent calcitriol therapy on BMD changes is differ-
ent among VDR genotypes.
METHODS
Patients
To be eligible for the study, patients had to be recipients
of a first or second renal graft, to not have had previous
parathyroidectomy, and to be older than 20 years. Pa-
tients treated for hyperparathyroidism with vitamin D at
the time of RT were not excluded. The study was per-
formed according to the Declaration of Helsinki and was
approved by both the local Ethics Committee and the
nationwide Central Committee (Direccio´n General de
Farmacia, Spanish Ministry of Health, Madrid). All par-
ticipants gave informed consent.
Study design
Ninety consecutive renal allograft recipients were dou-
ble blindly randomized to one of two therapies: calcium
supplementation with 0.5 g of elemental calcium given
with a meal per day (calcium lactogluconate; Calcium-
Sandoz Forte, Basel, Switzerland), plus placebo every
other day; or calcium supplementation plus 0.5 lg oral
calcitriol (Hoffman La Roche, Basel, Switzerland) ev-
ery other day. Placebo or calcitriol were administered at
night. Compliance was ascertained by the pill-counting
method. Placebo pills were undistinguishable from cal-
citriol, contained the vehicle, and were kindly provided by
Hoffman La Roche. Therapy was initiated during the first
3 days after surgery, and was continued for the first three
months; thereafter, calcium supplementation alone was
maintained until completing the first post-transplantation
year. If severe hypercalcemia (>11.3 mg/dL) occurred,
therapy was interrupted for one week, and then restarted
or eventually stopped definitively. If diuretics were clin-
ically needed, loop diuretics but not thiazides were al-
lowed. Estrogen replacement therapy, bisphosphonates,
and other drugs known to affect bone metabolism were
not used during the study.
The primary end point was the change in BMD
3 months after RT. We also tested whether an effect of cal-
citriol was maintained at 1 year post-transplantation. The
group to which a patient was assigned was not known to
the investigator until bone densitometry was performed
1 year after RT. Routine laboratory measurements in-
cluding serum calcium and phosphorus were performed
twice a week during the first 2 weeks, and then once a
week for an additional 4 weeks. From this time to the end
of the first three months, serum calcium and phosphorus
were measured once every 2 weeks. Thereafter, regular
measurements were made as per clinical practice but not
less than once per month. Intact parathyroid hormone
(PTH) was measured before RT and 3 and 12 months
thereafter. Calcitriol and gonadal hormones were mea-
sured at 3 and 12 months post-transplantation. Twenty-
four hour urine collections were analyzed for creatinine,
protein, calcium, and phosphorus at 3 and 12 months after
RT.
Immunosuppression
Immunosuppression consisted of antithymocyte glob-
ulin (Lymphoglobulin; Pasteur Merieux, Lyon, France)
for induction, and prednisone, cyclosporine, and my-
cophenolate mofetil (MMF) or azathioprine for main-
tenance. The dose of prednisone was 0.3 mg/kg bw/day
during the first 3 months, and then was gradually reduced
to 10 mg/day by one year. Cyclosporine was started at
8 mg/kg bw/day, and then adjusted according to total
blood levels. Episodes of acute rejection were initially
treated with three boluses of 500 mg of intravenous
methylprednisolone. Resistant episodes were treated
with a 10-day course of OKT3 (5 mg/day) (Muromonab
CD3; Ortho Pharmaceutical, Raritan, NJ, USA).
Laboratory measurements
Serum calcium, albumin, phosphorus, and total al-
kaline phosphatase were measured using a comput-
erized autoanalyzer (Hitachi; Boehringer Manheim,
Germany). Total serum calcium concentration was ad-
justed for serum albumin [17]. Serum concentrations
of intact PTH were determined by a solid-phase, two-
site chemiluminescent enzyme immunometric assay on
a DPC-Immulite automated immunoassay analyzer (Di-
agnostics Product Corporation, Los Angeles, CA, USA)
(normal range 12–72 ng/mL; intra- and intercoefficient
of variation 5% and 7%, respectively). Serum calcitriol
levels were measured by a cytoreceptor assay (Nichols In-
stitute, San Juan de Capistrano, CA, USA). Total blood
CsA levels were quantified by fluorescence polarization
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immunoassay (FPIA) assay using a monoclonal antibody
(Abbott Laboratories, Abbott Park, IL, USA). Venous
bicarbonate concentration was determined anaerobically
using a blood gas analyzer (ABL; Radiometer, Copen-
hagen, Denmark). Serum estradiol levels were measured
by chemiluminescent competitive immnunoassay (Diag-
nostics Product Corporation), and free testosterone lev-
els by radioimmunoassay (RIA) (Diagnostics Product
Corporation).
Assessment of calcium intake
A three-day dietary diary was obtained from every pa-
tient both at 3 and 12 months after RT. From the food
intake records, the average daily ingestion of protein, cal-
cium, and phosphorus were calculated by computerized
diet analysis [18].
Bone densitometry
BMD measured in grams per square centimeter was
determined using dual energy x-ray absorption bone
densitometry (DEXA) with the Hologic QDR 2000 den-
sitometer (Hologic, Waltham, MA, USA) for the lum-
bar spine (L1-L4 in anteroposterior direction), total hip,
femoral neck, trochanter, intertrochanteric region, and
Ward triangle. BMD was also expressed in standard de-
viation units as Z scores (comparison with age- and
sex-matched mean from normal Spanish population).
Changes of BMD during follow-up were expressed as
percentage from baseline. Precision errors are as follows:
L1-L4, 1.4%; total hip, 1%; femoral neck, 1.8%.
Radiography
A radiograph of the thoracic and lumbar spine was per-
formed at study entry, and repeated if patients suffered
from symptoms of vertebral fractures.
Genomic typing of VDR alleles
DNA was purified from 3 mL of blood by standard
methods, and VDR alleles were typed by using a poly-
merase chain reaction (PCR)-based assay developed to
ascertain the presence of a polymorphic Bsm I restric-
tion site at single-nucleotide polymorphism (SNP) no.
154410 (http//www.ncbi.nlm.nih.gov/SNP) as previously
described [13]. The presence of the restriction site defines
the b allele, and its absence defines the B allele.
Statistical analysis
Sample size was calculated assuming a 5% and 2.5%
decrease in BMD during the first 3 months post-
transplantation in the placebo and calcitriol group, re-
spectively. To the 41 patients in each group for an a of
0.05, and a power of 0.8, 10% was added for estimated
losses. VDR polymorphisms were typed after RT, and
thus, no stratification was performed. Randomization was
performed by opening a sealed envelope with the lowest
available study number.
Between-group comparisons of continuous variables
were performed by Student t test or U-Mann test as ap-
propriate. Categorical variables were compared by Fisher
exact test. Generalized linear model (GLM) was used to
compare BMD changes between groups of therapy af-
ter adjusting for confounding variables. The interaction
between group of therapy and VDR genotype in deter-
mining BMD changes, while adjusting for confounding
variables, was also performed using the GLM. Evidence
for interaction was based on the nominal two-sided P val-
ues from the F test for the term treatment-by-genotype
interaction. All data are expressed as mean ± SD, and a
P value < 0.05 was considered significant. All compu-
tations were made using the SPSS 11.0 for Windows
(Chicago, IL, USA).
RESULTS
Patients
Ninety consecutive renal graft recipients transplanted
in our hospital were included. Four patients in the placebo
group were excluded: 2 lost their grafts for technical rea-
sons, 1 suffered irreversible rejection in the first 3 months,
and 1 received a graft with primary non-function. Thus,
41 patients in the placebo group and 45 in the calcitriol
group completed the study. Three patients in the placebo
group and 5 in the calcitriol group refused a reevalua-
tion 1 year after RT. In addition, 3 patients in the placebo
group and 4 in the calcitriol group had a creatinine clear-
ance ≤35 mL/min for more than 3 months just before
1 year after RT; to avoid the confounding effect of sec-
ondary hyperparathyroidism on BMD changes, they were
excluded from the analysis at this time point. Thus, 36 in
the calcitriol group and 35 in the placebo group were an-
alyzed 1 year after RT.
Demographic characteristics of the study patients at
entry are summarized in Table 1. No differences were
present between the two groups except for a tendency
for the calcitriol group to be younger. Clinical outcome
is summarized in Table 2. No difference between groups
was observed; interestingly, the number of patients with
hypercalcemia (>11 mg/dL), as well as hypercalcemia
episodes per patient, was similar in both groups. Table 3
shows biochemical parameters at entry and at 3 and
12 months after RT. Although PTH levels at entry were
similar in both groups, they were significantly lower in
the calcitriol group 3 months after grafting and tended
to be lower at 12 months. Calcitriol levels were similar
in both groups, but urinary calcium excretion was signifi-
cantly greater in the calcitriol group at 3 months, but not
at 12 months.
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Table 1. Demography of the study patients at entry
Calcitriol Placebo
(N = 45) (N = 41) P value
Age years 46.7 ± 12.2 51.1 ± 11.9 0.09
Gender M/F 37/8 30/11 0.44
Menopause 3/8 7/11 1
Diabetes % 14 (31) 8 (20) 0.32
Time on dialysis 18.5 ± 11.2 18.8 ± 9.3 0.9
months
HLA mismatches 3.8 ± 1 4 ± 0.8 0.2
(ABDR)
Retransplant % 2.2 4.9 0.2
Vitamin D therapy 7 (16) 8 (20) 0.78
on dialysis %
Body mass index g/cm2 24 ± 3.4 25 ± 4.9 0.26
VDR polymorphism 21/16/8 19/18/4 0.51
(BsmI) bb/Bb/BB
Table 2. Clinical outcome 3 and 12 months post-transplantation
Calcitriol Placebo P value
Body mass index g/cm2
3 months 25.6 ± 3.5 26.6 ± 4 0.2
12 months 28.1 ± 4.2 28.6 ± 4.4 0.6
Delayed function % 11 (24.4) 11 (27) 0.8
Patients with acute rejection %
3 months 5 (11) 4 (10) 1
12 months 7 (19) 6 (17) 1
Cumulative prednisone g
3 months 2.8 ± 0.7 2.8 ± 0.7 0.5
12 months 6.3 ± 1 6.3 ± 1 0.7
CsA levels ng/mL
3 months 247.5 ± 64.4 254.8 ± 65 0.6
12 months 243.6 ± 183 209 ± 75 0.3
Calcium intake mg/day
3 months 962.8 ± 392.6 852.8 ± 403.7 0.2
12 months 892.1 ± 398 935.7 ± 560 0.7
Protein intake g/kg/day
3 months 1.2 ± 0.4 1.1 ± 0.4 0.25
12 months 1.1 ± 0.5 1 ± 0.5 0.4
Loop diuretics %
3 months 13 12 0.8
12 months 13 10 1
Hypercalcemia ≥11 mg/dL
Patients (3 mo/12 mo) % 4.4/5.5 9.8/8.6 1/0.7
Episodes/patient 0.02 ± 0.2/ 0.12 ± 0.5/ 0.2/0.4
(3 mo/12 mo) 0.03 ± 0.2 0.1 ± 0.5
Stop study medication 0 0 1
Patients evaluated: calcitriol group, 45 at 3 months, and 36 at 1 year; placebo
group, 41 at 3 months, and 35 at 1 year.
Table 4 shows absolute values of BMD at entry and 3
and 12 months after RT. Probably related to their older
age, placebo patients had lower BMD values at entry than
patients in the calcitriol group; this difference did not
reach statistical significance when expressed as Z score
(data not shown). Figure 1 shows BMD changes from
baseline to 3 and 12 months after RT in the calcitriol and
placebo groups, adjusted for age, body mass index, base-
line BMD, and PTH levels. Patients treated with calcitriol
preserved their BMD at the total hip significantly better
than those on placebo at both time points (3 months:
0.04 ± 3.3 vs. −1.93 ± 3.2%, P = 0.01; 12 months: 0.32 ±
4.8 vs. −2.17 ± 4.4%, P = 0.03). At 3 months, for an alpha
Table 3. Laboratory measurements before (baseline), and 3 and 12
months after transplantation
Calcitriol Placebo
(N = 45) (N = 41)
Creatinine mg/dL
3 months 1.39 ± 0.4 1.4 ± 0.5
12 months 1.37 ± 0.3 1.3 ± 0.4
Creatinine clearance mL/min
3 months 71.6 ± 24.5 69.2 ± 26.6
12 months 83.7 ± 30 76 ± 30
Proteinuria g/day
3 months 0.07 ± 0.2 0.11 ± 0.3
12 months 0.1 ± 0.5 0.1 ± 0.2
Calcium mg/dL
Baseline 9.6 ± 0.8 9.7 ± 0.7
3 months 10 ± 0.5 10 ± 0.6
12 months 9.95 ± 0.6 9.8 ± 0.5
Phosphate mg/dL
Baseline 5.1 ± 1.7 5.1 ± 1.5
3 Months 3.2 ± 0.7 3.4 ± 0.8
12 months 3.7 ± 0.6 3.8 ± 0.7
Bicarbonate mEq/L
3 months 27 ± 3 26.7 ± 2.4
12 months 27.3 ± 2.5 27.6 ± 2.6
Alkaline phosphatase U/L
Baseline 140 ± 90 145 ± 100
3 months 206 ± 104.2 216.8 ± 121.3
12 months 205.5 ± 58 188 ± 63.5
PTH pg/mL
Baseline 197.1 ± 229.4 191.4 ± 183.5
3 months 61.4 ± 42.2 85.7 ± 53.1a
12 months 67.3 ± 33.7 82.6 ± 37 b
Calcitriol pg/mL
3 months 33 ± 20.2 30.8 ± 15.6
12 months 32.6 ± 11 36.7 ± 12.5
Calciuria mg/kg/day
3 months 3 ± 1.6 2.2 ± 1.3 a
12 months 2.3 ± 1.5 2.4 ± 1.3
TRP %
3 months 66.5 ± 12.1 69.1 ± 11
12 months 74.5 ± 7.8 75.3 ± 7.6
Testosterone ng/mL
3 months 13.7 ± 6.6 14 ± 5.8
(N = 37) (N = 30)
12 months 12.7 ± 5.6 15 ± 5
(N = 29) (N = 27)
Estradiol ng/mL
3 months 80.3 ± 46.1 70.8 ± 100.5
(N = 8) (N = 11)
12 months 65.9 ± 52 74 ± 117
(N = 7) (N = 8)
Patients evaluated: calcitriol group, 45 at 3 months, and 36 at 1 year; placebo
group: 41 at 3 months, and 35 at 1 year.
aP = 0.02 placebo vs. calcitriol.
bP = 0.08 placebo vs. calcitriol.
of 0.05, the calculated power was 80%. At the different re-
gions in the proximal femur, significant differences were
noted 3 months after RT at the intertrochanter (1 ± 4
vs. −1.4 ± 3.8%, P = 0.01) and Ward’s triangle (1.86 ±
9.4 vs. −3.86 ± 10%, P = 0.01), and after 12 months at
trochanter (−1.04 ± 5.4 vs. −5.33 ± 5.3%, P = 0.001) and
Ward’s triangle (1.55 ± 13 vs. −6.05 ± 14%, P = 0.02).
Differences did not reach statistical significance at the
femoral neck or at the lumbar spine. No patient suffered
a symptomatic fracture during the study period.
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Table 4. Absolute values of bone mineral density in the calcitriol and
placebo groups
Baseline 3 months 12 months
Lumbar spine g/cm2
Calcitriol (N = 45) 1.02 ± 0.12 0.99 ± 0.11 –
Placebo (N = 41) 0.98 ± 0.12c 0.95 ± 0.12 –
Calcitriol (N = 36) 1.03 ± 0.12 1 ± 0.12 0.99 ± 0.10
Placebo (N = 35) 0.98 ± 0.11c 0.95 ± 0.11c 0.93 ± 0.11b
Femoral neck g/cm2
Calcitriol (N = 45) 0.81 ± 0.11 0.81 ± 0.11 –
Placebo (N = 41) 0.76 ± 0.10a 0.75 ± 0.11a
Calcitriol (N = 36) 0.82 ± 0.11 0.82 ± 0.11 0.82 ± 0.11
Placebo (N = 35) 0.76 ± 0.11b 0.75 ± 0.12a 0.74 ± 0.10a
Trochanteric region g/cm2
Calcitriol (N = 45) 0.70 ± 0.13 0.69 ± 0.11 –
Placebo (N = 41) 0.66 ± 0.12 0.64 ± 0.12b –
Calcitriol (N = 36) 0.69 ± 0.12 0.68 ± 0.12 0.68 ± 0.12
Placebo (N = 35) 0.66 ± 0.12 0.64 ± 0.13 0.63 ± 0.12b
Intertrochanteric region g/cm2
Calcitriol (N = 45) 1.06 ± 0.16 1.08 ± 0.12 –
Placebo (N = 41) 1.03 ± 0.16 1.01 ± 0.12a –
Calcitriol (N = 36) 1.06 ± 0.16 1.07 ± 0.12 1.07 ± 0.12
Placebo (N = 35) 1.03 ± 0.15 1.01 ± 0.12b 1.01 ± 0.13b
Ward’s triangle g/cm2
Calcitriol (N = 45) 0.64 ± 0.15 0.65 ± 0.12 –
Placebo (N = 41) 0.57 ± 0.11b 0.55 ± 0.12a –
Calcitriol (N = 36) 0.63 ± 0.16 0.64 ± 0.14 0.64 ± 0.15
Placebo (N = 35) 0.58 ± 0.12 0.56 ± 0.13a 0.54 ± 0.14a
Total hip g/cm2
Calcitriol (N = 45) 0.91 ± 0.14 0.91 ± 0.12 –
Placebo (N = 41) 0.87 ± 0.13 0.85 ± 0.11b –
Calcitriol (N = 36) 0.91 ± 0.14 0.91 ± 0.12 0.91 ± 0.12
Placebo (N = 35) 0.87 ± 0.13 0.85 ± 0.12b 0.85 ± 0.12b
For each region, the values of the subgroup of patients who were studied at
baseline, 3 and 12 months after transplantation, are also given. Data shown are
mean ± SD.
aP ≤ 0.01 placebo vs. calcitriol.
bP < 0.05 placebo vs. calcitriol.
cP < 0.1 and ≥ 0.05 placebo vs. calcitriol.
A significant and inverse correlation between pre-
transplant PTH levels and BMD changes at the lumbar
spine from baseline to 3 months after RT was observed
(r = −0.42, P = 0.0001). However, the magnitude of
pre-existing hyperparathyroidism did not correlate with
BMD changes at the proximal femur (r = −0.005 for
femoral neck; r = 0.05 for total hip).
Figure 2 shows adjusted BMD changes from baseline
to 3 months after RT, in both groups as a function of
the VDR genotype. At the total hip, significant differ-
ences between calcitriol and placebo groups were ob-
served only in patients with the at-risk allele (B) of the
VDR polymorphism (P = 0.04); in addition, a signifi-
cant treatment-by-genotype interaction was detected in
the GLM after adjusting for confounding variables (P =
0.03). Such interaction was not observed 1 year after RT
(data not shown).
DISCUSSION
This randomized and double-blind clinical trial shows
that intermittent dose calcitriol during the first 3 months
after RT plus oral calcium supplementation during 1 year
decreased the rate of bone loss at the total hip, as com-
pared to calcium supplementation alone. In addition,
this therapy more rapidly decreased post-transplantation
PTH levels. This beneficial effect was not associated
with an increase of hypercalcemic episodes and no pa-
tient had to stop study medication. Finally, the benefi-
cial effect of intermittent calcitriol in terms of preventing
bone loss at the total hip was more pronounced in re-
cipients with the at-risk allele of the BsmI VDR gene
polymorphism.
The use of corticosteroids is regarded as an important
cause of post-transplant osteoporosis. Among treatment
options in non-renal patients, calcium combined with
active vitamin D [10, 11], calcitonin [10], and bisphos-
phonates [7, 19] have had proven efficacy. We used oral
calcium supplementation both in the calcitriol and con-
trol group in order to reach the recommendations of the
American Rheumatological Association for prevention
of osteoporosis in patients under corticosteroid treatment
[20]. The supplementation with 0.5 g of elemental calcium
to the average 900 mg/day of calcium intake (Table 2) pro-
vided a total of 1 to 1.5 g/day as recommended. Because
of the risk of hypercalcemia, we used low-dose intermit-
tent calcitriol at night. Indeed, hypercalcemia episodes
and renal function were similar in both groups, and no
patient had to stop study medications during the study
(Table 2).
Previous studies have demonstrated that a high pro-
portion of recipients have subnormal calcitriol levels
3 months after RT [21]. Our finding that intermittent cal-
citriol induces a more pronounced decline of PTH lev-
els at 3 and 12 months after RT (Table 3) suggests that
this therapy may help to prevent persistent hyperparathy-
roidism in renal transplant recipients. Patients treated
with intermittent calcitriol had similar calcitriol levels
3 months after RT to the placebo group, but this occurred
with 30% lower prevailing PTH levels (Table 3). In addi-
tion, urinary calcium excretion was significantly higher
3 months after RT in the intermittent calcitriol group
(Table 3). This cannot be explained by calcitriol-induced
bone loss because this group showed a better preserva-
tion of BMD. Thus, differences in the urinary calcium
excretion probably reflect a higher intestinal calcium ab-
sorption in the intermittent calcitriol group. These find-
ings confirm that enrolled patients were compliant with
prescription.
In the present study, the intermittent calcitriol and
placebo groups were comparable, both at baseline and
during follow-up, with respect to variables that can influ-
ence BMD changes after RT (Tables 1 and 2). However,
despite randomization, mean age of the placebo group
tended to be greater than that of the intermittent cal-
citriol group. As a consequence, baseline BMD at differ-
ent regions was also lower in this group (Table 4). Thus,
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Fig. 1. Changes of bone mineral density (BMD) at different regions 3 and 12 months after transplantation, in the calcitriol and placebo groups.
Values are adjusted for age, BMI, baseline BMD, and parathyroid hormone levels. Mean ± SE.
changes of BMD after RT were adjusted for age and base-
line BMD.
Few randomized prospective studies have addressed
the effect of calcium plus vitamin D in the preven-
tion of early bone loss after RT [12]. The study by De
Sevaux et al [12] compared daily 0.25 lg of 1-alpha-OH
Vitamin D plus 1 g of elemental calcium with no treat-
ment in the first 6 months after RT. Bone loss was par-
tially prevented at lumbar spine and different regions
of the proximal femur. In the present study, we used a
lower dose of oral calcium supplementation because our
goal was to provide the recommended daily intake. More-
over, the intermittent low dose of active vitamin D was
given only during the first 3 months. Our main finding
was that intermittent calcitriol prevented bone loss at the
intertrochanteric region, Ward’s triangle, and total hip,
3 months after RT (Fig. 1). Interestingly, such a prevent-
ing effect was maintained 12 months after RT (Fig. 1).
BMD changes at the femoral neck were also improved by
intermittent calcitriol, although differences did not reach
statistical difference (Fig. 1).
In contrast to the findings from De Sevaux [12], the
placebo and calcitriol groups further decreased their
BMD at the lumbar spine between 3 and 12 months after
RT (Fig. 1). It is possible that the dose and duration of
calcitriol therapy required to prevent bone loss at this site
was insufficient in our study. However, higher cancellous
bone volume is a known feature of patients with renal
hyperparathyroidism, and reduction of vertebral BMD
after RT may in part be attributable to resolution of sec-
ondary hyperparathyroidism, resulting in a loss of the
trophic effects of PTH on cancellous bone. The signifi-
cant and inverse correlation between the magnitude of
pre-existing hyperparathyroidism and BMD changes at
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Fig. 2. Percent change of BMD 3 months after transplantation as a
function of vitamin D receptor (VDR) genotype and therapy group.
Values are adjusted for age, BMI, baseline BMD, and PTH levels. P
value is for the treatment by genotype interaction. Mean ± SE.
lumbar spine but not at the proximal femur, found in the
present study, points to this hypothesis [13].
Bone disease after RT comprises heterogeneous alter-
ations ranging from high- to low-bone turnover [5]. In
addition, one study found a considerable proportion of
patients with mineralization defect [22]. Because corti-
costeroid therapy decreases intestinal calcium absorption
and favors secondary hyperparathyroidism, the concomi-
tant use of low-dose calcium and intermittent calcitriol
avoids negative calcium balance. This effect seems ap-
propriate in terms of avoiding bone loss independent of
the underlying bone histology.
Genetic factors are major determinants of bone mass,
and VDR gene variants have been found among the
main markers of BMD [23]. However, the association
between BMD and VDR polymorphism has been incon-
sistent [24]. Recent studies have clarified that the effect
of VDR polymorphism on BMD decreases with age [25,
26] and increases in populations with either low calcium
intake or depleted vitamin D [25, 27]. Our finding that
bone loss was similar among genotypes in recipients un-
der placebo (Fig. 2) contrasts with our previous report
[13], and suggests that the calcium supplementation used
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in the present study could override the genetic effect.
We also observed that the preventive effect of intermit-
tent calcitriol on the rate of bone loss after RT was more
prominent in the recipients with at least one at-risk allele
(Fig. 2). A similar finding has been reported in non-renal
populations [15, 16]. These findings point to functional
differences of VDR at intestinal and/or bone cells, but
little evidence is available about the functional conse-
quences of the SNP analyzed. Sequence variants at the
3′-UTR of the VDR gene have been implicated with
changes in mRNA stability [28], while two other poly-
morphisms located at the promoter [29] and 5′-UTR [30]
of the gene have been reported to influence the bind-
ing of transcription factor Cdx-2 and translation initia-
tion, respectively. None of these SNPs corresponds to
the common VDR polymorphism analyzed in the present
study, but it remains possible that the BsmI polymor-
phism studied is in linkage disequilibrium with other
functional DNA changes within the VDR gene or in its
proximity. Finally, because a beneficial effect of intermit-
tent calcitriol was shown in all genotypes, our findings do
not suggest that it is necessary to target individual inter-
vention in prospective transplant recipients as a function
of VDR genotype.
Our study has several potential limitations. First, we
did not systematically search for fractures or vertebral
deformities during the study, and only in the case of symp-
toms were conventional x-ray studies performed. How-
ever, fractures occur late after RT, and more frequently
involve the appendicular skeleton [5]. Obviously, future
studies are required to know whether the fracture rate is
also reduced by our therapy. Finally, the number of pa-
tients re-evaluated 1 year after RT was reduced to 80%–
85% in both groups, thus decreasing the statistical power
as compared to 3 months. As a consequence, results at 1
year might be less discriminating.
CONCLUSION
Our data provide evidence that treatment with low-
dose calcium supplements and intermittent calcitriol after
RT is safe, decreases PTH levels more rapidly, and pre-
vents the bone loss at the proximal femur. Future studies
in these patients are needed to assess whether the treat-
ment is effective in decreasing the fracture rate.
ACKNOWLEDGMENT
This study has been funded by FIS 98/0786 (Instituto de Salud Carlos
III; Spanish Ministry of Health), the Spanish Society of Nephrology, and
Instituto Reina Sofı´a de Investigacio´n.
Reprint requests to Dr. Armando Torres, Unidad de Investigacio´n,
Hospital Universitario de Canarias, Ofra s/n, 38320 La Laguna, Tenerife,
Spain.
E-mail: atorres@ull.es
REFERENCES
1. JULIAN BA, QUARLES LD, NIEMAN KM: Musculoskeletal complica-
tions after renal transplantation: Pathogenesis and treatment. Am
J Kidney Dis 19:99–120, 1992
2. HORBER FF, CASEZ JP, STEIGER U, et al: Changes in bone mass early
after kidney transplantation. J Bone Min Res 9:1–9, 1994
3. ALMOND MK, KWAN JTC, EVANS K, CUNNINGHAM J: Loss of regional
bone mineral density in the first 12 months following renal trans-
plantation. Nephron 66:52–57, 1994
4. GROTZ W, NAGEL C, POESCHEL D, et al: Effect of ibandronate on
bone loss and renal function after kidney transplantation. J Am Soc
Nephrol 12:1530–1537, 2001
5. TORRES A, LORENZO V, SALIDO E: Calcium metabolism and skele-
tal problems after transplantation. J Am Soc Nephrol 13:551–558,
2002
6. ROJAS E, CARLINI RG, CLESCA P, et al: The pathogenesis of osteodys-
trophy after renal transplantation as detected by early alterations
in bone remodeling. Kidney Int 63:1915–1923, 2003
7. WALLACH S, COHEN S, REID DM, et al: Effects of risedronate treat-
ment on bone density and vertebral fracture in patients on corticos-
teroid therapy. Calcif Tissue Int 67:277–285, 2000
8. FAN SLS, ALMOND MK, BALL E, et al: Pamidronate therapy as pre-
vention of bone loss following renal transplantation. Kidney Int
57:684–690, 2000
9. TORRES A, LORENZO V, HERNA´NDEZ D, et al: Bone disease and intact
PTH levels in predialysis, hemodialysis, and CAPD patients: Evi-
dence of a better bone response to PTH in dialysis patients. Kidney
Int 47:1434–1442, 1995
10. SAMBROOK P, BIRMINGHAM J, KELLY P, et al: Prevention of corticos-
teroid osteoporosis. A comparison of calcium, calcitriol, and calci-
tonin. N Engl J Med 328:1747–1752, 1993
11. ADACHI JD, BENSEN WG, BIANCHI F, et al: Vitamin D and calcium
in the prevention of corticosteroid induced osteoporosis: A 3 year
follow-up. J Rheumatol 23:95–1000, 1996
12. DE SE´VAUX RGL, HOITSMA AJ, CORSTENS FHM, WETZELS JFM:
Treatment with vitamin D and calcium reduces bone loss after renal
transplantation: A randomized study. J Am Soc Nephrol 13:1608–
1614, 2002
13. TORRES A, MACHADO M, CONCEPCIO´N MT, et al: Influence of vitamin
D receptor genotype on bone mass changes after renal transplanta-
tion. Kidney Int 50:1726–1733, 1996
14. GUARDIOLA J, XIOL X, SALLIE R, et al: Influence of the vitamin D
receptor gene polymorphism on bone loss in men after liver trans-
plantation. Ann Int Med 131:752–755, 1999
15. FERRARI S, MANEN D, BONJOUR JP, et al: Bone mineral mass and
calcium and phosphate metabolism in young men: Relationships
with vitamin D receptor polymorphisms. J Clin Endocrinol Metab
84:2043–2048, 1999
16. GRAAFMANS WC, LIPS P, OOMS ME, et al: Effect of vitamin D sup-
plementation on the bone mineral density of the femoral neck is
associated with vitamin D receptor genotype. J Bone Miner Res
12:1241–1245, 1997
17. PAYNE RB, LITTLE AJ, WILLIAMS RB, MILNER JR: Interpretation
of serum calcium in patients with abnormal serum proteins. BMJ
4:643–646, 1973
18. LORENZO V, DE BONIS E, RUFINO M, et al: Caloric rather than pro-
tein deficiency predominates in stable chronic hemodialysis patents.
Nephrol Dial Transplant 10:1885–1889, 1995
19. SAAG KG, EMKEY R, SCHNITZER TJ, et al: Alendronate for the
prevention and treatment of glucocorticoid-induced osteoporosis.
Glucocorticoid-induced Osteoporosis Intervention Study Group. N
Engl J Med 339:292–299, 1998
20. RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF
GLUCOCORTICOID-INDUCED OSTEOPOROSIS: 2001 update. American
College of Rheumatology Ad-Hoc Committee on glucocorticoid-
induced osteoporosis. Arthritis Rheum 44:1496–1503, 2001
21. DE SE´VAUX RGL, HOITSMA AJ, VAN HOOF HJC, et al: Abnormal
vitamin D metabolism and loss of bone mass after renal transplan-
tation. Nephron Clin Pract 93:c21–c28, 2003
22. FAUGERE MC, MAWAD H, QI Q, et al: High prevalence of low
turnover and occurrence of osteomalacia after kidney transplan-
tation. J Am Soc Nephrol 11:1093–1099, 2000
712 Torres et al: Intermittent calcitriol and calcium after transplantation
23. MORRISON NA, QI JC, TOKITA A, et al: Prediction of bone density
from vitamin D receptor alleles. Nature 367:284–287, 1994
24. NGUYEN TV, BLANGERO J, EISMAN JA: Genetic epidemiological ap-
proaches to the search for osteoporosis genes. J Bone Miner Res
15:392–401, 2000
25. FERRARI SL, RIZOLI R, SLOSMAN DO, BONJOUR JP: Do dietary cal-
cium and age explain the controversy surrounding the relationship
between bone mineral density and vitamin D receptor gene poly-
morphism? J Bone Miner Res 13:363–370, 1998
26. SAINZ J, VAN TOURNOT JM, LORO ML, et al: Vitamin D receptor gene
polymorphism and bone density in prepubertal American girls of
Mexican descent. N Engl J Med 337:77–82, 1997
27. BERNAD M, JARAMILLO G, AGUADO P, et al: Polymorphism of the
gene of vitamin D receptor and bone mineral density in post-
menopausal women. Med Clin (Barc) 112:651–655, 1999
28. DURRIN LK, HAILE RW, INGLES SA, COETZEE GA: Vitamin D re-
ceptor 3′-untranslated polymorphisms: Lack of effect on mRNA
stability. Biochim Biophys Acta 1453:311–320, 1999
29. ARAI H, MIYAMOTO KI, YOSHIDA M, et al: The polymorphism in
the caudal-related homeodomain protein Cdx-2 binding element in
the human vitamin D receptor gene. J Bone Min Res 16:1256–1264,
2001
30. ARAI H, MIYAMOTO K, TAKETANI Y, et al: Vitamin D receptor gene
polymorphism in the translation initiation codon effect on protein
activity and relation to bone mineral density in Japanese women. J
Bone Min Res 12:915–921, 1997
